Immune Tolerance Network Industry Outreach Meeting

Jeffrey B. Matthews jbm at smartt.com
Thu Nov 4 17:30:52 EST 1999


This is a multi-part message in MIME format.

------=_NextPart_000_006E_01BF26B8.674CFD40
Content-Type: text/plain;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable

CHICAGO, IL =96 November 3, 1999 =96 The Immune Tolerance Network, the =
$144 million dollar immunological research initiative supported by the =
National Institutes of Health and the Juvenile Diabetes Foundation, will =
hold an informational meeting with industry representatives on December =
7, 1999 in Washington, D.C. The meeting, open to all interested parties, =
is intended to familiarize biotechnology and pharmaceutical companies =
interested in tolerance research with the mission and goals of the =
Network and facilitate industry participation in clinical trial and =
tolerance assay development performed by Network investigators.


The Immune Tolerance Network is a seven-year initiative aimed at =
developing and assessing clinical strategies to induce and measure =
immune tolerance. The Network will maintain a broad focus, overseeing =
clinical trial and tolerance assay development in islet and kidney =
transplantation, autoimmune disorders, such as diabetes, lupus, =
rheumatoid arthritis and multiple sclerosis and others, as well as =
allergy & asthma.=20


The Network is comprised of over 70 of the world=92s leading experts in =
immune tolerance and will conduct clinical trials at =
soon-to-be-established centers around the country. Dr. Jeffrey =
Bluestone, of the University of Chicago, a recognized leader in the =
field, is the Network Director.=20


"We have established a collaboration that will be open and inclusive, =
with the flexibility to capitalize on emerging opportunities for any =
potential tolerogenic approaches," says Dr. Bluestone. "A very important =
aspect of this project is the extension of this collaboration to partner =
with biotechnology and pharmaceutical companies in Network trials, so =
that we take full advantage of our collective resources and expertise."


Among the major topics for discussion at the meeting will be =
intellectual property and technology transfer issues, maintaining =
confidentiality and regulatory compliance for the Network-industry =
collaborations. Specifically, the Network plans to open a discussion on =
plans for multi-drug trials involving proprietary agents from different =
companies. Combination therapies of such agents are a largely untapped =
resource, the precedent having been set recently in an NIAID-sponsored =
trial using agents developed independently by Ortho/Johnson & Johnson =
and Novartis.=20


"In the past, there have been a number of hurdles to initiating such =
trials, stemming both from proprietary and logistical concerns," said =
Dr. Rose of the NIAID. "The Immune Tolerance Network offers an =
opportunity to solve many of these problems through large patient =
populations, a strong FDA interface and access to first rate clinical =
researchers."=20


The meeting will be attended by key members of the Network Executive, as =
well as several representatives from the NIH and the FDA who specialize =
in technology transfer and regulatory issues.=20




Companies interested in sending representatives to the meeting are asked =
to contact Kate Tomlin, of The EMMES Corporation at (301) 299-8655 by =
November 15, 1999 to reserve a space. More information can be found at =
the ITN website, www.immunetolerance.org.=20




###






The Immune Tolerance Network is a seven year, $144 million dollar =
clinical research program founded in October 1999 to solicit, develop, =
implement and assess clinical strategies and biological assays for the =
purposes of inducing, maintaining and monitoring tolerance in humans for =
kidney and islet transplantation, autoimmune diseases and allergy & =
asthma. The ITN is jointly sponsored by the National Institute of =
Allergy and Infectious Diseases, the National Institute of Diabetes and =
Digestive and Kidney Disease and the Juvenile Diabetes Foundation =
International.


------=_NextPart_000_006E_01BF26B8.674CFD40
Content-Type: text/html;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable

<!DOCTYPE HTML PUBLIC "-//W3C//DTD W3 HTML//EN">
<HTML>
<HEAD>

<META content=3Dtext/html;charset=3Diso-8859-1 =
http-equiv=3DContent-Type><!DOCTYPE HTML PUBLIC "-//W3C//DTD W3 =
HTML//EN">
<META content=3D'"MSHTML 4.72.3110.7"' name=3DGENERATOR>
</HEAD>
<BODY bgColor=3D#ffffff>
<DIV><FONT face=3DArial size=3D3>
<P align=3Djustify>CHICAGO, IL &ndash; November 3, 1999 &ndash; The =
Immune=20
Tolerance Network, the $144 million dollar immunological research =
initiative=20
supported by the National Institutes of Health and the Juvenile Diabetes =

Foundation, will hold an informational meeting with industry =
representatives on=20
December 7, 1999 in Washington, D.C. The meeting, open to all interested =

parties, is intended to familiarize biotechnology and pharmaceutical =
companies=20
interested in tolerance research with the mission and goals of the =
Network and=20
facilitate industry participation in clinical trial and tolerance assay=20
development performed by Network investigators.</P>
<P align=3Djustify></P>
<P align=3Djustify>The Immune Tolerance Network is a seven-year =
initiative aimed=20
at developing and assessing clinical strategies to induce and measure =
immune=20
tolerance. The Network will maintain a broad focus, overseeing clinical =
trial=20
and tolerance assay development in islet and kidney transplantation, =
autoimmune=20
disorders, such as diabetes, lupus, rheumatoid arthritis and multiple =
sclerosis=20
and others, as well as allergy &amp; asthma. </P>
<P align=3Djustify></P>
<P align=3Djustify>The Network is comprised of over 70 of the =
world&rsquo;s=20
leading experts in immune tolerance and will conduct clinical trials at=20
soon-to-be-established centers around the country. Dr. Jeffrey =
Bluestone, of the=20
University of Chicago, a recognized leader in the field, is the Network=20
Director. </P>
<P align=3Djustify></P>
<P align=3Djustify>&quot;We have established a collaboration that will =
be open and=20
inclusive, with the flexibility to capitalize on emerging opportunities =
for any=20
potential tolerogenic approaches,&quot; says Dr. Bluestone. &quot;A very =

important aspect of this project is the extension of this collaboration =
to=20
partner with biotechnology and pharmaceutical companies in Network =
trials, so=20
that we take full advantage of our collective resources and =
expertise.&quot;</P>
<P align=3Djustify></P>
<P align=3Djustify>Among the major topics for discussion at the meeting =
will be=20
intellectual property and technology transfer issues, maintaining=20
confidentiality and regulatory compliance for the Network-industry=20
collaborations. Specifically, the Network plans to open a discussion on =
plans=20
for multi-drug trials involving proprietary agents from different =
companies.=20
Combination therapies of such agents are a largely untapped resource, =
the=20
precedent having been set recently in an NIAID-sponsored trial using =
agents=20
developed independently by Ortho/Johnson &amp; Johnson and Novartis. =
</P>
<P align=3Djustify></P>
<P align=3Djustify>&quot;In the past, there have been a number of =
hurdles to=20
initiating such trials, stemming both from proprietary and logistical=20
concerns,&quot; said Dr. Rose of the NIAID. &quot;The Immune Tolerance =
Network=20
offers an opportunity to solve many of these problems through large =
patient=20
populations, a strong FDA interface and access to first rate clinical=20
researchers.&quot; </P>
<P align=3Djustify></P>
<P align=3Djustify>The meeting will be attended by key members of the =
Network=20
Executive, as well as several representatives from the NIH and the FDA =
who=20
specialize in technology transfer and regulatory issues. </P>
<P align=3Djustify></P>
<P align=3Djustify>&nbsp;</P>
<P align=3Djustify>Companies interested in sending representatives to =
the meeting=20
are asked to contact Kate Tomlin, of The EMMES Corporation at (301) =
299-8655 by=20
November 15, 1999 to reserve a space. More information can be found at =
the ITN=20
website, <A =
href=3D"http://www.immunetolerance.org">www.immunetolerance.org</A>.=20
</P>
<P align=3Djustify></P>
<P align=3Djustify>&nbsp;</P>
<P align=3Dcenter>###</P>
<P align=3Djustify></P>
<P align=3Djustify>&nbsp;</P>
<P align=3Djustify>&nbsp;</P>
<DIR></FONT><B><I><FONT size=3D3>
<P align=3Dcenter>The Immune Tolerance Network is a seven year, $144 =
million=20
dollar clinical research program founded in October 1999 to solicit, =
develop,=20
implement and assess clinical strategies and biological assays for the =
purposes=20
of inducing, maintaining and monitoring tolerance in humans for kidney =
and islet=20
transplantation, autoimmune diseases and allergy &amp; asthma. The ITN =
is=20
jointly sponsored by the National Institute of Allergy and Infectious =
Diseases,=20
the National Institute of Diabetes and Digestive and Kidney Disease and =
the=20
Juvenile Diabetes Foundation=20
International.</P></DIR></B></I></FONT></DIV></BODY></HTML>

------=_NextPart_000_006E_01BF26B8.674CFD40--






More information about the Bioforum mailing list